RPTXRepare Therapeutics Inc
RPTX
Repare Therapeutics Inc1,044
Mkt Cap
$90.7MVolume
497,416.0052W High
$4.0752W Low
$0.89PE Ratio
-1.25RPTX Fundamentals
Price
$2.12Prev Close
$2.11Open
$2.1250D MA
$1.83Beta
1.05Avg. Volume
193,530.26EPS (Annual)
-$2.00P/B
0.79Rev/Employee
$414,550.39Repare Therapeutics Inc. (NASDAQ:RPTX) Receives Consensus Recommendation of "Hold" from Analysts
Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) has been given an average recommendation of "Hold" by the seven brokerages that are covering the company, Marketbeat Ratings reports. One...
MarketBeat·2d ago
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into...
Business Wire·4d ago
Stock Traders Purchase High Volume of Call Options on Repare Therapeutics (NASDAQ:RPTX)
Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw some unusual options trading activity on Monday. Stock investors bought 13,699 call options on the stock. This represents an increase of...
MarketBeat·7d ago
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to...
PR Newswire·7d ago
Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value
Repare Therapeutics agrees to be acquired by XenoTherapeutics, offering shareholders cash, CVRs, and future milestone potential as the deal targets an early 2026 closing.read more...
Benzinga·8d ago
RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Repare Therapeutics Inc. (NASDAQ: RPTX) to XenoTherapeutics, Inc. is fair to Repare shareholders. Upon closing of...
Business Wire·10d ago
Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Repare...
PR Newswire·10d ago
Repare Therapeutics Inc. (RPTX) Reports Break-Even Earnings for Q3
Repare Therapeutics (RPTX) delivered earnings and revenue surprises of +100.00% and +132.40%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that it has entered into a definitive arrangement agreement (the...
Business Wire·10d ago
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy...
Business Wire·1mo ago